People · Operator
Named in public records as an officer, director or promoter · active 2010–2017 · Pharmaceuticals, Biotechnology, Other Energy, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2013 |
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| Seres Health, Inc. | — | Pharmaceuticals | Series C | $123.6M | $2.3B | 2014 |
| Codiak BioSciences, Inc. | — | Biotechnology | Series C | $107.5M | $3.1B | 2015 |
| Axcella Health Inc. | — | Biotechnology | Series C | $92.8M | $105.5M | 2015 |
| BIND Biosciences Inc | — | Biotechnology | Series B | $51.4M | $345.2M | 2010 |
| LS9, Inc. | — | Other Energy | Series B | $30.0M | $348.1M | 2010 |
| Selventa, Inc. | — | Other Health Care | Series A | $5.5M | $100.2M | 2011 |
| BG Medicine, Inc. | — | Biotechnology | Seed | $2.5M | $22.2M | 2010 |
Noubar Afeyan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Noubar Afeyan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barton Hutt | 3 | 14 |
| Robert Langer | 2 | 36 |
| Lorence Kim | 2 | 5 |
| Lee Babiss | 2 | 5 |
| Stephane Bancel | 2 | 4 |
| PETER HUTT | 2 | 4 |
| Charles Cooney | 2 | 4 |
| John Mendlein | 2 | 4 |
| Henri Termeer | 2 | 3 |
| David Berry | 2 | 3 |
| Stephen Hoge | 2 | 2 |
| Steven Gillis | 1 | 23 |
| Robert S Langer | 1 | 14 |
| Vinod Khosla | 1 | 12 |
| Michael Grey | 1 | 10 |
| James Wright | 1 | 9 |
| Peter Nieh | 1 | 7 |
| Scott Minick | 1 | 7 |
| Stephen Hall | 1 | 7 |
| Robert Crane | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.